December 10, 2015: Inception and Celgene Enter Strategic Collaboration to Advance Novel Therapeutics for Inflammatory Bowel Disease.
Inception IBD Inc., a Québec-based biotechnology company backed by Versant Ventures, Fonds de solidarité FTQ, and Inserm Transfer Initiative, today announced an exclusive, strategic collaboration with Celgene Corp. to discover and develop novel therapeutics for ulcerative colitis and Crohn’s disease.
See businesswire.com for more.
December 10, 2015: Inception IBD Completes Financing Led by Versant Ventures, Bolsters Management Team.
Inception IBD today announced the completion of a $14.1 million Series A financing led by Versant Ventures and joined by Fonds de solidarité FTQ, along with existing investor Inserm Transfert Initiative (ITI). The funds will be used to advance a portfolio of therapeutics targeting the underlying pathogenesis of inflammatory bowel disease (IBD). In conjunction with the financing, Dr. Paul C. Anderson, a veteran research and development executive, was appointed Chief Scientific Officer and Site Head of Inception Sciences’ new Montréal research facility.
See businesswire.com for more.
June 25, 2014: Versant’s Inception plants its booming biotech startup model in Montreal.
Close on the heels of a new discovery deal this week with Roche ($RHHBY), Versant Venture's incubation team at Inception Sciences outlined plans this week to establish a new research team in Montreal's biotech hub, adding a third site to Inception that will hunt down new pacts and create new biotechs for product-hungry pharma companies.
See fiercebiotech.com for more.
June 24, 2014: Press Release - Montreal - Versant Ventures Expands Canadian Operations with Launch of Inception Sciences in Montreal - Drug Discovery Engine to Create New Companies.
Versant Ventures, a global life sciences venture capital firm, continues its Canadian growth strategy with the launch of biopharmaceutical incubator Inception Sciences in Montreal. Versant, with Inception Sciences, will be working to launch new companies that can accelerate the commercialization of scientific research in the province of Quebec.
June 24, 2014: Press Release - Inception Sciences Appoints Clare Ozawa as Chief Operating Officer
San Diego, Calif. and Vancouver, Canada – Inception Sciences, a drug discovery incubator that launches new companies in collaboration with academia and pharmaceutical companies, today announced that Clare Ozawa, Ph.D. was named Chief Operating Officer.
Clare Ozawa joined Inception Sciences in January 2011 as founding Chief Business Officer. In her new role as COO, Clare will have overall responsibility for Inception’s global operations, including strategic business development, and oversight of Inception’s launch of a new site in Montreal, Canada. Press Release: PDF
June 23, 2014: Press Release - Tapping UCSF Invention, Roche and Versant Dive Into Myelin Repair
June 23, 2014: Roche announces partnership to discover novel disease-modifying therapies for multiple sclerosis.
Roche announced today that it has entered into an exclusive partnership with Inception Sciences, Inc., and Versant Ventures to create Inception 5, a new company dedicated to the research and development of novel small molecule remyelinating therapies for patients with multiple sclerosis.
Nov. 18, 2013: Press Release - Bayer HealthCare, Inception Sciences and Versant Ventures Join Forces to Develop Innovative Therapeutics for Retinal Eye Diseases.
Bayer HealthCare has entered into an exclusive collaboration with Inception Sciences, Inc. and Versant Ventures. Inception Sciences and Bayer will jointly conduct early research in the area of ophthalmology, in a newly created company called “Inception 4”. The goal of this new alliance is to develop treatment options, focused on a novel target and pathway, for patients with eye diseases, such as wet age-related macular degeneration and geographic atrophy.
Oct. 10, 2012: Press Release - Roche Announces Alliance to Discover Novel Treatments for Sensorineural Hearing Loss
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into an exclusive partnership with Versant Ventures and Inception Sciences to create a drug discovery incubator, Inception 3, for the treatment of sensorineural hearing loss.
Nov. 29, 2011: Fresh Off Amira Success, Versant’s Bolzon and San Diego’s Prasit Begin Anew with Inception. See Xconomy.com.
July 27, 2011: Versant Supports Biotech Incubator From Amira Co-Founder. See Venture Capital Dispatch for full article